ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 67 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 3.62 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $542,000 | -0.4% | 164,200 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $544,000 | -1.8% | 164,200 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $554,000 | -8.3% | 164,200 | +4.2% | 0.00% | -50.0% |
| Q1 2020 | $604,000 | -77.7% | 157,600 | -64.8% | 0.01% | -71.4% |
| Q4 2019 | $2,704,000 | -20.1% | 447,600 | 0.0% | 0.03% | -22.2% |
| Q3 2019 | $3,384,000 | -30.4% | 447,600 | +24.7% | 0.04% | +200.0% |
| Q2 2019 | $4,860,000 | +400.0% | 358,800 | +100.0% | 0.01% | +100.0% |
| Q1 2019 | $972,000 | +265.4% | 179,400 | +450.3% | 0.01% | +200.0% |
| Q3 2018 | $266,000 | -16.4% | 32,600 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $318,000 | -3.0% | 32,600 | -13.5% | 0.00% | 0.0% |
| Q1 2018 | $328,000 | +1.9% | 37,700 | -1.8% | 0.00% | 0.0% |
| Q3 2017 | $322,000 | -16.6% | 38,400 | +100.0% | 0.00% | 0.0% |
| Q1 2017 | $386,000 | – | 19,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Beryl Capital Management LLC | 4,898,927 | $6,246,132 | 0.70% |
| Yakira Capital Management, Inc. | 620,019 | $790,524 | 0.22% |
| Crystalline Management Inc. | 230,817 | $294,292 | 0.21% |
| DELTEC ASSET MANAGEMENT LLC | 475,000 | $605,625 | 0.14% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 2,283,979 | $2,912,073 | 0.12% |
| PenderFund Capital Management Ltd. | 123,444 | $213 | 0.06% |
| FIFTH LANE CAPITAL, LP | 100,000 | $127,000 | 0.04% |
| CSS LLC/IL | 476,831 | $607,960 | 0.04% |
| Penserra Capital Management LLC | 220,858 | $280 | 0.01% |
| King Wealth Management Group | 16,000 | $20 | 0.00% |